[
    [
        {
            "time": "",
            "original_text": "光大证券：药明康德买入评级",
            "features": {
                "keywords": [
                    "光大证券",
                    "药明康德",
                    "买入评级"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "光大证券：药明康德买入评级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "君联资本业绩集中爆发：1年拿下12个IPO，百亿人民币基金进入收获期",
            "features": {
                "keywords": [
                    "君联资本",
                    "IPO",
                    "业绩爆发",
                    "百亿基金"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "君联资本业绩集中爆发：1年拿下12个IPO，百亿人民币基金进入收获期",
                "Correlation": 4,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-01-31",
            "original_text": "【医药-药明康德(603259)】江琦、池陈森：公司点评：业绩预增符合预期，继续保持高速增长-20190131",
            "features": {
                "keywords": [
                    "药明康德",
                    "业绩预增",
                    "高速增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药-药明康德(603259)】江琦、池陈森：公司点评：业绩预增符合预期，继续保持高速增长-20190131",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]